U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07237659) titled 'Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA' on Nov. 12.
Brief Summary: This phase 1a and 1b study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of NTR-1011 in healthy adults and in adult patients with systemic lupus erythematosus and rheumatoid arthritis. The main goals of this study are to determine the safety profile of NTR-1011 across subcutaneous and intravenous dose levels, understand how the drug behaves in the body, characterize its biological activity through relevant pharmacodynamic markers, assess ...